This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PALACE2)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Celgene
ClinicalTrials.gov Identifier:
NCT01212757
First received: September 29, 2010
Last updated: May 18, 2017
Last verified: May 2017
  Purpose

The purpose of this study is to determine whether apremilast is safe and effective in the treatment of patients with psoriatic arthritis.

Apremilast is proposed to improve signs and symptoms of psoriatic arthritis (tender and swollen joints, pain, physical function) in treated patients.


Condition Intervention Phase
Psoriatic Arthritis Drug: Apremilast 20mg Drug: Apremilast 30mg Drug: Placebo + 20 mg Apremilast Drug: Placebo + 30 mg Apremilast Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator, Outcomes Assessor
Primary Purpose: Treatment
Official Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis

Resource links provided by NLM:


Further study details as provided by Celgene:

Primary Outcome Measures:
  • Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 [ Time Frame: Baseline and Week 16 ]

    Percentage of participants with an American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:

    • ≥ 20% improvement in 78 tender joint count;
    • ≥ 20% improvement in 76 swollen joint count; and
    • ≥ 20% improvement in at least 3 of the 5 following parameters:

      • Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
      • Patient's global assessment of disease activity (measured on a 100 mm VAS);
      • Physician's global assessment of disease activity (measured on a 100 mm VAS);
      • Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI));
      • C-Reactive Protein.


Secondary Outcome Measures:
  • Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 16 [ Time Frame: Baseline and Week 16 ]
    The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement in functional ability.

  • Percentage of Participants With an ACR 20 Response at Week 24 [ Time Frame: Baseline and Week 24 ]

    Percentage of participants with an American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:

    • ≥ 20% improvement in 78 tender joint count;
    • ≥ 20% improvement in 76 swollen joint count; and
    • ≥ 20% improvement in at least 3 of the 5 following parameters:

      • Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
      • Patient's global assessment of disease activity (measured on a 100 mm VAS);
      • Physician's global assessment of disease activity (measured on a 100 mm VAS);
      • Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI));
      • C-Reactive Protein.

  • Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 24 [ Time Frame: Baseline and Week 24 ]
    The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement in functional ability.

  • Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 16 [ Time Frame: Baseline and Week 16 ]
    The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. Higher scores indicate a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from Baseline score indicates an improvement.

  • Percentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 16 [ Time Frame: Baseline and Week 16 ]

    Modified PsARC response is defined as improvement in at least 2 of the 4 measures, at least one of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures:

    • 78 tender joint count,
    • 76 swollen joint count,
    • Patient global assessment of disease activity, measured on a 100 mm visual Analog scale (VAS), where 0 mm = lowest disease activity and 100 mm = highest;
    • Physician global assessment of disease activity, measured on a 100 mm VAS, where 0 mm = lowest disease activity and 100 mm = highest.

    Improvement or worsening in joint counts is defined as decrease or increase, respectively, from baseline by ≥ 30%, and improvement or worsening in global assessments is defined as decrease or increase, respectively, from baseline by ≥ 20 mm VAS.


  • Change From Baseline in Patient's Assessment of Pain at Week 16 [ Time Frame: Baseline and Week 16 ]
    The participant was asked to place a vertical line on a 100-mm visual analog scale on which the left-hand boundary (score = 0 mm) represents "no pain," and the right-hand boundary (score = 100 mm) represents "pain as severe as can be imagined." The distance from the mark to the left-hand boundary was recorded in millimeters.

  • Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 16 [ Time Frame: Baseline and Week 16 ]

    The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone):

    1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right.

    The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.


  • Change From Baseline in Dactylitis Severity Score at Week 16 [ Time Frame: Baseline and Week 16 ]
    Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet will be rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

  • Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 16 [ Time Frame: Baseline and Week 16 ]

    The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the:

    • 28 tender joint count (TJC),
    • 28 swollen joint count (SJC),
    • Patient's Global Assessment of Disease Activity measured on a 10 cm visual analog scale (VAS), where 0 cm = lowest disease activity and 10 cm = highest;
    • Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest.

    The CDAI score ranges from 0-76 where lower scores indicate less disease activity.

    The following thresholds of disease activity have been defined for the CDAI:

    Remission: ≤ 2.8 Low Disease Activity: > 2.8 and ≤ 10 Moderate Disease Activity: > 10 and ≤ 22 High Disease Activity: > 22.


  • Change From Baseline in the Disease Activity Score (DAS28) at Week 16 [ Time Frame: Baseline and Week 16 ]

    The DAS28 measures the severity of disease at a specific time and is derived from the following variables:

    • 28 tender joint count
    • 28 swollen joint count, which do not include the distal interphalangeal (DIP) joints, the hip joint, or the joints below the knee;
    • C-reactive protein (CRP)
    • Patient's global assessment of disease activity.

    DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.


  • Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 16 [ Time Frame: Baseline and Week 16 ]

    The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The FACIT-Fatigue scale score ranges from 0 to 52, with higher scores denoting lower levels of fatigue.

    A positive change from baseline score indicates an improvement.


  • Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 24 [ Time Frame: Baseline and Week 24 ]
    The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. Higher scores indicate a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from Baseline score indicates an improvement.

  • Percentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 24 [ Time Frame: Baseline and Week 24 ]

    Modified PsARC response is defined as improvement in at least 2 of the 4 measures, at least one of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures:

    • 78 tender joint count,
    • 76 swollen joint count,
    • Patient global assessment of disease activity, measured on a 100 mm visual Analog scale (VAS), where 0 mm = lowest disease activity and 100 mm = highest;
    • Physician global assessment of disease activity, measured on a 100 mm VAS, where 0 mm = lowest disease activity and 100 mm = highest.

    Improvement or worsening in joint counts is defined as decrease or increase, respectively, from baseline by ≥ 30%, and improvement or worsening in global assessments is defined as decrease or increase, respectively, from baseline by ≥ 20 mm VAS.


  • Change From Baseline in Patient's Assessment of Pain at Week 24 [ Time Frame: Baseline and Week 24 ]
    The participant was asked to place a vertical line on a 100-mm visual analog scale on which the left-hand boundary (score = 0 mm) represents "no pain," and the right-hand boundary (score = 100 mm) represents "pain as severe as can be imagined." The distance from the mark to the left-hand boundary was recorded in millimeters.

  • Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 24 [ Time Frame: Baseline and Week 24 ]

    The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone):

    1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right.

    The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.


  • Change From Baseline in Dactylitis Severity Score at Week 24 [ Time Frame: Baseline and Week 24 ]
    Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet will be rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

  • Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 24 [ Time Frame: Baseline and Week 24 ]

    The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the:

    • 28 tender joint count (TJC),
    • 28 swollen joint count (SJC),
    • Patient's Global Assessment of Disease Activity measured on a 10 cm visual analog scale (VAS), where 0 cm = lowest disease activity and 10 cm = highest;
    • Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest.

    The CDAI score ranges from 0-76 where lower scores indicate less disease activity.

    The following thresholds of disease activity have been defined for the CDAI:

    Remission: ≤ 2.8; Low Disease Activity: > 2.8 and ≤ 10; Moderate Disease Activity: > 10 and ≤ 22; High Disease Activity: > 22.


  • Change From Baseline in the Disease Activity Score (DAS28) at Week 24 [ Time Frame: Baseline and Week 24 ]

    The DAS28 measures the severity of disease at a specific time and is derived from the following variables:

    • 28 tender joint count
    • 28 swollen joint count, which do not include the DIP joints, the hip joint, or the joints below the knee;
    • C-reactive protein (CRP)
    • Patient's global assessment of disease activity.

    DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.


  • Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 24 [ Time Frame: Baseline and Week 24 ]
    The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The FACIT-Fatigue scale score ranges from 0 to 52, with higher scores denoting lower levels of fatigue. A positive change from baseline score indicates an improvement.

  • Percentage of Participants With MASES Improvement ≥ 20% at Week 16 [ Time Frame: Baseline and Week 16 ]

    Percentage of participants with pre-existing enthesopathy whose MASES improved by ≥ 20% from Baseline after 16 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone):

    1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right.

    The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.


  • Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 16 [ Time Frame: Baseline and Week 16 ]

    Percentage of participants with pre-existing dactylitis whose dactylitis severity score improved by ≥ 1 after 16 weeks of treatment.

    Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.


  • Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Response at Week 16 [ Time Frame: Baseline and Week 16 ]

    A EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score.

    A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 3.2.

    A Moderate Response is defined as either:

    • an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of less than or equal to 5.1 or,
    • an improvement (decrease) in the DAS28 of more than 1.2 and attainment of a DAS28 score of greater than 3.2.

  • Percentage of Participants With MASES Improvement ≥ 20% at Week 24 [ Time Frame: Baseline and Week 24 ]

    Percentage of participants with pre-existing enthesopathy whose MASES improved by ≥ 20% from Baseline after 24 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone):

    1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right.

    The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.


  • Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 24 [ Time Frame: Baseline and Week 24 ]

    Percentage of participants with pre-existing dactylitis whose dactylitis severity score improved by ≥ 1 after 24 weeks of treatment.

    Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.


  • Percentage of Participants With Good or Moderate EULAR Response at Week 24 [ Time Frame: Baseline and Week 24 ]

    EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score.

    A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 3.2.

    A Moderate Response is defined as either:

    • an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of less than or equal to 5.1 or,
    • an improvement (decrease) in the DAS28 of more than 1.2 and attainment of a DAS28 score of greater than 3.2.

  • Percentage of Participants With a ACR 50 Response at Week 16 [ Time Frame: Baseline and Week 16 ]

    Percentage of participants with an American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:

    • ≥ 50% improvement in 78 tender joint count;
    • ≥ 50% improvement in 76 swollen joint count; and
    • ≥ 50% improvement in at least 3 of the 5 following parameters:

      • Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
      • Patient's global assessment of disease activity (measured on a 100 mm VAS);
      • Physician's global assessment of disease activity (measured on a 100 mm VAS);
      • Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI));
      • C-Reactive Protein.

  • Percentage of Participants With an ACR 70 Response at Week 16 [ Time Frame: Baseline and Week 16 ]

    Percentage of participants with an American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:

    • ≥ 70% improvement in 78 tender joint count;
    • ≥ 70% improvement in 76 swollen joint count; and
    • ≥ 70% improvement in at least 3 of the 5 following parameters:

      • Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
      • Patient's global assessment of disease activity (measured on a 100 mm VAS);
      • Physician's global assessment of disease activity (measured on a 100 mm VAS);
      • Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI));
      • C-Reactive Protein.

  • Percentage of Participants With an ACR 50 Response at Week 24 [ Time Frame: Baseline and Week 24 ]

    Percentage of participants with an American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:

    • ≥ 50% improvement in 78 tender joint count;
    • ≥ 50% improvement in 76 swollen joint count; and
    • ≥ 50% improvement in at least 3 of the 5 following parameters:

      • Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
      • Patient's global assessment of disease activity (measured on a 100 mm VAS);
      • Physician's global assessment of disease activity (measured on a 100 mm VAS);
      • Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI));
      • C-Reactive Protein.

  • Percentage of Participants With a ACR 70 Response at Week 24 [ Time Frame: Baseline and Week 24 ]

    Percentage of participants with an American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:

    • ≥ 70% improvement in 78 tender joint count;
    • ≥ 70% improvement in 76 swollen joint count; and
    • ≥ 70% improvement in at least 3 of the 5 following parameters:

      • Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
      • Patient's global assessment of disease activity (measured on a 100 mm VAS);
      • Physician's global assessment of disease activity (measured on a 100 mm VAS);
      • Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI));
      • C-Reactive Protein.

  • Percentage of Participants Achieving a MASES Score of Zero at Week 16 [ Time Frame: Week 16 ]

    Percentage of participants with pre-existing enthesopathy whose MASES improves to 0 after 16 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone):

    1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right.

    The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.


  • Percentage of Participants Achieving a Dactylitis Score of Zero at Week 16 [ Time Frame: Week 16 ]

    Percentage of participants with pre-existing dactylitis whose dactylitis severity score improves to zero after 16 weeks of treatment.

    Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.


  • Percentage of Participants Achieving a MASES Score of Zero at Week 24 [ Time Frame: Week 24 ]

    Percentage of participants with pre-existing enthesopathy whose MASES improves to 0 after 24 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone):

    1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right.

    The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.


  • Percentage of Participants Achieving a Dactylitis Score of Zero at Week 24 [ Time Frame: Week 24 ]

    Percentage of participants with pre-existing dactylitis whose dactylitis severity score improves to zero after 24 weeks of treatment.

    Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.


  • Percentage of Participants With a ACR 20 Response at Week 52 [ Time Frame: Baseline and Week 52 ]

    Percentage of participants with an American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:

    • ≥ 20% improvement in 78 tender joint count;
    • ≥ 20% improvement in 76 swollen joint count; and
    • ≥ 20% improvement in at least 3 of the 5 following parameters:

      • Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
      • Patient's global assessment of disease activity (measured on a 100 mm VAS);
      • Physician's global assessment of disease activity (measured on a 100 mm VAS);
      • Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI));
      • C-Reactive Protein.

    Two-sided 95% confidence interval is based on the Clopper-Pearson method.


  • Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 52 [ Time Frame: Baseline and Week 52 ]
    The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement in functional ability.

  • Change From Baseline in the SF-36 Physical Functioning Scale Score at Week 52 [ Time Frame: Baseline and Week 52 ]
    The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. Higher scores indicate a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from Baseline score indicates an improvement.

  • Percentage of Participants With a Modified PsARC Response at Week 52 [ Time Frame: Baseline and Week 52 ]

    Modified PsARC response is defined as improvement in at least 2 of the 4 measures, at least one of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures:

    • 78 tender joint count,
    • 76 swollen joint count,
    • Patient global assessment of disease activity, measured on a 100 mm visual Analog scale (VAS), where 0 mm = lowest disease activity and 100 mm = highest;
    • Physician global assessment of disease activity, measured on a 100 mm VAS, where 0 mm = lowest disease activity and 100 mm = highest.

    Improvement or worsening in joint counts is defined as decrease or increase, respectively, from baseline by ≥ 30%, and improvement or worsening in global assessments is defined as decrease or increase, respectively, from baseline by ≥ 20 mm VAS.

    Two-sided 95% confidence interval is based on the Clopper-Pearson method.


  • Change From Baseline in the Patient Assessment of Pain at Week 52 [ Time Frame: Baseline and Week 52 ]
    The participant was asked to place a vertical line on a 100-mm visual analog scale on which the left-hand boundary (score = 0 mm) represents "no pain," and the right-hand boundary (score = 100 mm) represents "pain as severe as can be imagined." The distance from the mark to the left-hand boundary was recorded in millimeters.

  • Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 52 [ Time Frame: Baseline and Week 52 ]

    The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone):

    1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right.

    The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.


  • Change From Baseline in the Dactylitis Severity Score at Week 52 [ Time Frame: Baseline and Week 52 ]
    Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet will be rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

  • Change From Baseline in the CDAI Score at Week 52 [ Time Frame: Baseline and Week 52 ]

    The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the:

    • 28 tender joint count (TJC),
    • 28 swollen joint count (SJC),
    • Patient's Global Assessment of Disease Activity measured on a 10 cm visual analog scale (VAS), where 0 cm = lowest disease activity and 10 cm = highest;
    • Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest.

    The CDAI score ranges from 0-76 where lower scores indicate less disease activity.

    The following thresholds of disease activity have been defined for the CDAI:

    Remission: ≤ 2.8 Low Disease Activity: > 2.8 and ≤ 10 Moderate Disease Activity: > 10 and ≤ 22 High Disease Activity: > 22.


  • Change From Baseline in the DAS28 at Week 52 [ Time Frame: Baseline and Week 52 ]

    The DAS28 measures the severity of disease at a specific time and is derived from the following variables:

    • 28 tender joint count
    • 28 swollen joint count, which do not include the DIP joints, the hip joint, or the joints below the knee;
    • C-reactive protein (CRP)
    • Patient's global assessment of disease activity.

    DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.


  • Change From Baseline in the FACIT-Fatigue Scale Score at Week 52 [ Time Frame: Baseline and Week 52 ]
    The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The FACIT-Fatigue scale score ranges from 0 to 52, with higher scores denoting lower levels of fatigue. A positive change from baseline score indicates an improvement.

  • Percentage of Participants With MASES Improvement ≥ 20% at Week 52 [ Time Frame: Baseline and Week 52 ]

    Percentage of participants with pre-existing enthesopathy whose MASES improved by ≥ 20% from Baseline after 52 weeks. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone):

    1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right.

    The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

    Two-sided 95% confidence interval is based on the Clopper-Pearson method.


  • Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 52 [ Time Frame: Baseline and Week 52 ]

    Percentage of participants with pre-existing dactylitis whose dactylitis severity score improved by ≥ 1 after 52 weeks.

    Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

    Two-sided 95% confidence interval is based on the Clopper-Pearson method.


  • Percentage of Participants Achieving Good or Moderate EULAR Response at Week 52 [ Time Frame: Baseline and Week 52 ]

    A EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score.

    A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 3.2.

    A Moderate Response is defined as either:

    • an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of less than or equal to 5.1 or,
    • an improvement (decrease) in the DAS28 of more than 1.2 and attainment of a DAS28 score of greater than 3.2.

  • Percentage of Participants With an ACR 50 Response at Week 52 [ Time Frame: Baseline and Week 52 ]

    Percentage of participants with an American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:

    • ≥ 50% improvement in 78 tender joint count;
    • ≥ 50% improvement in 76 swollen joint count; and
    • ≥ 50% improvement in at least 3 of the 5 following parameters:

      • Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
      • Patient's global assessment of disease activity (measured on a 100 mm VAS);
      • Physician's global assessment of disease activity (measured on a 100 mm VAS);
      • Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI));
      • C-Reactive Protein.

    Two-sided 95% confidence interval is based on the Clopper-Pearson method.


  • Percentage of Participants With an ACR 70 Response at Week 52 [ Time Frame: Baseline and Week 52 ]

    Percentage of participants with an American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:

    • ≥ 70% improvement in 78 tender joint count;
    • ≥ 70% improvement in 76 swollen joint count; and
    • ≥ 70% improvement in at least 3 of the 5 following parameters:

      • Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
      • Patient's global assessment of disease activity (measured on a 100 mm VAS);
      • Physician's global assessment of disease activity (measured on a 100 mm VAS);
      • Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI));
      • C-Reactive Protein.

    Two-sided 95% confidence interval is based on the Clopper-Pearson method.


  • Percentage of Participants Achieving a MASES Score of Zero at Week 52 [ Time Frame: Week 52 ]

    Percentage of participants with pre-existing enthesopathy whose MASES improves to 0 after 24 weeks. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone):

    1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right.

    The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

    Two-sided 95% confidence interval is based on the Clopper-Pearson method.


  • Percentage of Participants Achieving a Dactylitis Score of Zero at Week 52 [ Time Frame: Week 52 ]

    Percentage of participants with pre-existing dactylitis whose dactylitis severity score improves to zero after 52 weeks.

    Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

    Two-sided 95% confidence interval is based on the Clopper-Pearson method.


  • Number of Participants With Adverse Events [ Time Frame: Up to 5 years ]

Enrollment: 488
Actual Study Start Date: September 27, 2010
Study Completion Date: January 25, 2017
Primary Completion Date: July 26, 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Apremilast 20mg
20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase
Drug: Apremilast 20mg
Apremilast 20 mg twice daily, orally
Other Name: CC-10004
Experimental: Apremilast 30mg
30 mg Apremilast tablets administered twice a day for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice a day for up to 4.5 years in the active treatment / long-term safety phase orally twice daily
Drug: Apremilast 30mg
Apremilast 30 mg twice daily, orally
Other Name: CC-10004
Placebo Comparator: Placebo + 20 mg Apremilast
Placebo + 20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 20 mg Apremilast twice daily at Week 16
Drug: Placebo + 20 mg Apremilast
Placebo + 20 mg Apremilast
Other Names:
  • Placebo
  • CC-10004
Placebo Comparator: Placebo + 30 mg Apremilast
Placebo + 30 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 30 mg Apremilast twice daily at Week 16.
Drug: Placebo + 30 mg Apremilast
Placebo + 30 mg Apremilast
Other Names:
  • Placebo
  • CC-10004

Detailed Description:
Psoriatic arthritis (PsA) is an inflammatory arthritis that occurs in 6-39% of psoriasis patients. The immunopathogenesis of PsA, which mirrors but is not identical to that seen in psoriatic plaques, reflects a complex interaction among resident dendritic, fibroblastic and endothelial cells, and inflammatory cells attracted to the synovium by cytokines and chemokines. Apremilast (CC-10004) is a novel oral agent that modulates multiple inflammatory pathways through targeted phosphodiesterase type 4 (PDE4) enzyme inhibition. Therefore, apremilast has the potential to be effective in the treatment of PsA.
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Males or females, aged ≥ 18 years at time of consent.
  • Have a diagnosis of Psoriatic Arthritis (PsA, by any criteria) of ≥ 6 months duration.
  • Meet the Classification Criteria for Psoriatic Arthritis (CASPAR) PsA at time of screening.
  • Must have been inadequately treated by disease-modifying antirheumatic drugs (DMARDs)
  • May not have axial involvement alone
  • Concurrent Treatment allowed with methotrexate, leflunomide, or sulfasalazine
  • Have ≥ 3 swollen AND ≥ 3 tender joints.
  • Males & Females must use contraception
  • Stable dose of nonsteroidal anti-inflammatory drugs (NSAIDs), narcotics and low dose oral corticosteroids allowed.

Exclusion Criteria:

  • Pregnant or breast feeding.
  • History of allergy to any component of the investigational product.
  • Hepatitis B surface antigen and/or Hepatitis C antibody positive at screening.
  • Therapeutic failure on > 3 agents for PsA or > 1 biologic tumor necrosis factor (TNF) blocker
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01212757

  Hide Study Locations
Locations
United States, Alabama
Clinical and Translational Research Center of Alabama, PC
Tuscaloosa, Alabama, United States, 35406
United States, Colorado
Denver Arthritis Clinic
Denver, Colorado, United States, 80230
United States, Connecticut
New England Research Associates, LLC
Trumbull, Connecticut, United States, 6611
United States, Florida
Centre For Rheumatology, Immun. And Arthritis
Fort Lauderdale, Florida, United States, 33334
DMI Research
Saint Petersburg, Florida, United States, 33710
University of South Florida
Tampa, Florida, United States, 33612
United States, Georgia
Arthritis and Rheumatology of Georgia
Atlanta, Georgia, United States, 30342
United States, Illinois
Michael Bukhalo MD SC
Arlington Heights, Illinois, United States, 60005
United States, Michigan
Associated Internal Medical Specialist, PC
Battle Creek, Michigan, United States, 49015
Advanced Rheumatology
Lansing, Michigan, United States, 48910
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
United States, Montana
Research West Incorporated
Kalispell, Montana, United States, 59901
United States, New York
University of Rochester Medical Center
Rochester, New York, United States, 14623
United States, North Carolina
Vital Research
Greensboro, North Carolina, United States, 27408
Unifour Medical Research Associatets LLC
Hickory, North Carolina, United States, 28602
United States, Pennsylvania
Rheumatic Disease Associates
Willow Grove, Pennsylvania, United States, 19090
United States, Texas
Metroplex Clinical Research Center
Dallas, Texas, United States, 75231
Baylor Research Institute
Dallas, Texas, United States, 75246-1613
Arthritis Care and Diagnostic Center
Dallas, Texas, United States, 75321
Luckster Enterprises
San Antonio, Texas, United States, 78232
United States, Washington
Seattle Rheumatology Associates
Seattle, Washington, United States, 98104
Tacoma Center for Arthritis Research, PS
Tacoma, Washington, United States, 98405
United States, Wisconsin
Rheumatology and Immunotherapy Center
Franklin, Wisconsin, United States, 53132
Belgium
CHU Brugmann
Bruxelles, Belgium, 1020
UZ Gent
Ghent, Belgium, 9000
UZ Leuven
Leuven, Belgium, 3000
University Hospital of Liege CHU Liege
Liège, Belgium, 4000
Bulgaria
Diagnostic and Consulting Centre 7
Sofia, Bulgaria, 1233
Multiprofile Hospital for Active Treatment Tokuda Hospital Sofia
Sofia, Bulgaria, 1407
17 Diagnostic and Consulting Centre Sofia EOOD
Sofia, Bulgaria, 1505
Multiprofile Hospital for Active Treatment Sv. Ivan Rilski
Sofia, Bulgaria, 1612
Diagnostic-Consultative Center "Sveta Anna"
Sofia, Bulgaria, 1709
Diagnostic and Consulting Centre 4
Varna, Bulgaria, 9010
Canada, Alberta
Rheumatology Research Associates
Edmonton, Alberta, Canada, T5M 0H4
Canada, British Columbia
PerCuro Clinical Research
Victoria, British Columbia, Canada, V8P5P6
Canada, Ontario
Anna Jaroszynska Private Practice
Burlington, Ontario, Canada, L7L0B7
William Bensen's Private Practice
Hamilton, Ontario, Canada, L8N1Y2
North Bay Dermatology Center
North Bay, Ontario, Canada, P1B 3Z7
Rheumatology Research Associates
Ottawa, Ontario, Canada, K1H 1A2
Wilderman Medical Clinic
Thornhill, Ontario, Canada, L4J1W3
Darryl Toth's Private Practice
Windsor, Ontario, Canada, N8W 1E6
Czechia
Revmatologie s.r.o.
Brno, Czechia, 638 00
MEDIPONT PLUS s.r.o..
Ceske Budejovice, Czechia, 370 01
L.K.N. Arthrocentrum s.r.o.
Hlucin, Czechia, 748 01
ARTMEDI UPD s.r.o.
Hostivice, Czechia, 253 01
Affidea Praha s.r.o
Praha 11, Czechia, 148 00
Revmatologicky ustav
Praha 2, Czechia, 128 50
Revmatologicka Ambulance
Praha 4, Czechia, 140 00
Revmatologicka Ambulance
Sokolov, Czechia, 356 01
PV - MEDICAL, s.r.o.
Zlin, Czechia, 760 01
Estonia
Parnu Hospital
Pärnu, Estonia, EE-80010
East Tallinn Central Hospital
Tallinn, Estonia, EE-11412
North Estonia Regional Hospital
Tallinn, Estonia, EE-13419
Clinical Research Centre Ltd
Tartu, Estonia, 50106
Tartu University Hospital
Tartu, Estonia, EE-51014
France
Hopital Universitaire Dupuytren
Limoges, France, 87042
Hopital Lariboisiere
Paris, France, 75010
Fondation Hôpital Saint-Joseph
Paris, France, 75014
Groupe Hospitalier Pitié- Salpétrière
Paris, France, 75651
Centre Hospitalier Lyon Sud
Pierre Benite, France, 69495
Germany
Charite - Universitätsmedizin Berlin
Berlin, Germany, 10117
Klinikum der Johann-Wolfgang Goethe-Universität
Frankfurt, Germany, 60590
Praxis Karin Rockwitz
Goslar, Germany, 38642
Synexus Clinical Research GmbH
Leipzig, Germany, 4103
Hungary
Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum
Debrecen, Hungary, 4032
Pest Megyei Flor Ferenc Korhaz
Kistarcsa, Hungary, 2143
Principal SMO Kft.
Makó, Hungary, 6900
Italy
Azienda Ospedaliera Universitaria San Martino
Genova, Italy, 16132
Ospedale Luigi Sacco
Milano, Italy, 20157
Seconda Universita degli Studi di Napoli
Napoli, Italy, 80130
IRCCS Policlinico San Matteo
Pavia, Italy, 27100
Universita di Pisa
Pisa, Italy, 56126
Ospedale Civile Maggiore Borgo Trento
Verona, Italy, 37126
Poland
NZOZ Osteo-Medic sc A. Racewicz J. Supronik
Bialystok, Poland, 15-351
Niepubliczny Zaklad Opieki Zdrowotnej REUMED
Lublin, Poland, 20-582
Instytut Reumatologii im. prof. dr hab. med. Eleonory Reicher
Warsaw, Poland, 02-637
Wojskowy Instytut Medyczny
Warszawa, Poland, 00-909
Synexus SCM Sp. z o.o.
Wroclaw, Poland, 50-088
Russian Federation
City Clinical Hospital #1 n.a. N.I.Pirogov
Moscow, Russian Federation, 119049
City Clinical Hospital #5
Nizhniy Novgorod, Russian Federation, 603005
St.Petersburg State Medical Academy n. a. I.I.Mechnikov
St. Petersburg, Russian Federation, 195067
Yaroslavl Regional Clinical Hospital
Yaroslavl, Russian Federation, 150062
South Africa
Nelson Mandela School Of Medicine
Durban, South Africa, 4091
Greenacres Hospital
Port Elizabeth, South Africa, 6057
Jacaranda Hospital
Pretoria, South Africa, 2
Spain
Hospital Universitario de Canarias
La Laguna, Spain, 38320
Hospital General Carlos Haya
Málaga, Spain, 29009
Hospital Sierrallana
Torrelavega, Spain, 39300
Taiwan
Chung Shan Medical University Hospital
Taichung, Taiwan, 402
Taichung Veterans General Hospital
Taichung, Taiwan, 40705
Cathay General Hospital
Taipei, Taiwan, 106
Taipei Veterans General Hospital
Taipei, Taiwan, 112
Chang Gung Medical Foundation-Linkou Branch
Taoyuan, Taiwan, 333
National Taiwan University Hospital
Tapei, Taiwan, 10002
United Kingdom
Basingstoke and North Hampshire Hospital
Basingstoke, United Kingdom, RG24 9NA
Cannock Chase Hospital
Cannock, United Kingdom, WS11 5XY
Chapel Allerton Hospital
Leeds, United Kingdom, LS7 4SA
Poole Hospital
Poole, United Kingdom, BH 1 5JB
Great Western Hospital
Swindon, United Kingdom, SN3 6BB
Sponsors and Collaborators
Celgene
Investigators
Study Director: Douglas Hough, M.D. Celgene
  More Information

Publications:
Responsible Party: Celgene
ClinicalTrials.gov Identifier: NCT01212757     History of Changes
Other Study ID Numbers: CC-10004-PSA-003
2010-018386-32 ( EudraCT Number )
Study First Received: September 29, 2010
Results First Received: April 21, 2014
Last Updated: May 18, 2017

Keywords provided by Celgene:
Psoriasis
Arthritis
Psoriatic Arthritis
inflammation
skin condition
inflammatory cells
apremilast
CC-10004
phosphodiesterase type 4

Additional relevant MeSH terms:
Arthritis
Arthritis, Psoriatic
Joint Diseases
Musculoskeletal Diseases
Spondylarthropathies
Spondylarthritis
Spondylitis
Spinal Diseases
Bone Diseases
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases
Apremilast
Thalidomide
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Immunosuppressive Agents
Immunologic Factors
Leprostatic Agents
Anti-Bacterial Agents
Anti-Infective Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances

ClinicalTrials.gov processed this record on July 14, 2017